Accounts Payable and Accrued Expenses |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable and Accrued Expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable and Accrued Expenses | Note 7 - Accounts Payable and Accrued Expenses At June 30, 2024, and December 31, 2023, accounts payable and accrued expenses consisted of the following:
(1) Other includes approximately $1.4 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||